Cargando…
Value drivers of development stage biopharma companies
OBJECTIVE: Scholars previously estimated research and development (R&D) costs of the internal drug development process. However, little is known about the costs and value arising from externally acquired therapeutics. This study identifies and estimates the magnitude of factors associated with B...
Autores principales: | Michaeli, Daniel Tobias, Yagmur, Hasan Basri, Achmadeev, Timur, Michaeli, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550717/ https://www.ncbi.nlm.nih.gov/pubmed/35038054 http://dx.doi.org/10.1007/s10198-021-01427-5 |
Ejemplares similares
-
Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
Outsourcing Biopharma R to India
por: Chowdhury, P
Publicado: (2011) -
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
Recepta biopharma portfolio: clinical and pre clinical development
por: Tuma, M Carolina
Publicado: (2014)